# GHK-Cu Copper Peptide Hair Research: The Controlled-Trial Readout > Copper peptide hair research, logged to source: a 45-patient GHK-combination RCT adding +71.5 hairs vs +9.6 placebo, C3H mouse follicle data, and AHK-Cu analog dermal-papilla findings. GHK-Cu detail, with the combination caveat flagged. The follicle record for GHK-Cu and its close copper-tripeptide analogs — the controlled human signal, the animal basis, and the combination-formula caveat, each surfaced plainly. ## The strongest controlled signal Copper Peptide Hair Research has one headline controlled result, and the readout leads with it. In a 6-month trial of 45 men with androgenetic alopecia (Norwood-Hamilton II to V), a topical complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide (ALAVAX) increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, against 9.6 for placebo (p<0.05), with no adverse events in any group [4]. That is the cleanest human efficacy signal for a GHK-containing topical in the literature. It carries one load-bearing caveat, flagged immediately: the trial tested a combination of 5-ALA and GHK, not pure GHK-Cu. The hair-count gain cannot be attributed to the copper peptide alone, because 5-aminolevulinic acid is independently photodynamically active. The result is strong evidence for the combination formula and supportive — not conclusive — evidence for the GHK component. This is the honest read of the most-cited hair dataset. ## The animal and analog basis Beneath the human trial sits a preclinical foundation. Peptide-copper complexes stimulated hair-follicle activity and growth in C3H mice, the early animal-model result that put copper peptides into hair research in the first place [9]. It establishes a follicle-stimulating effect for the class, in vivo, decades before the human combination trial. The mechanistic detail comes from a close analog. AHK-Cu, the alanyl analog of GHK-Cu, at 10^-12 to 10^-9 M stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells in vitro; at 10^-9 M it reduced apoptosis, raising the Bcl-2/Bax ratio and lowering cleaved caspase-3 and PARP [13]. The readout flags this carefully: the apoptosis and proliferation data are from AHK-Cu, not GHK-Cu, and are cited as analog context — a plausible mechanism for the copper-tripeptide class, not a direct GHK-Cu efficacy measurement. ## A non-androgenic mechanism What makes the copper-peptide hair hypothesis distinct is the proposed mechanism. The effect is described as non-androgenic — acting through angiogenesis and Wnt/beta-catenin-driven anagen entry rather than through DHT or 5-alpha-reductase blockade. The reported hair studies showed no change in testosterone or estradiol, consistent with a hormone-independent follicle effect [4]. That positions copper peptides differently from androgen-pathway interventions: not a DHT blocker, but a follicle-environment signal that extends the active growth phase and supports the dermal papilla. The angiogenic arm is the same VEGF/FGF-2 program documented in the [GHK-Cu collagen research](/research) wound literature [6], here applied to the perifollicular vasculature. It is a coherent mechanism, supported across mouse, ex vivo human follicle, and analog cell data, with the controlled human endpoint resting on the combination formula. ## Delivery: why the route matters for hair The hair studies that work share a delivery strategy, and the readout flags it because it explains why off-the-shelf application may underperform. The C16-modified and combination formulations, the microneedle and dermal-infusion delivery used in scalp studies, and the analog work all bypass the native penetration ceiling that limits free GHK on intact skin. Free GHK is highly hydrophilic, clogP -2.24, so passive scalp penetration is poor without enhancement [15]. The 45-patient trial applied its complex topically at 50 to 100 mg/mL, a high concentration relative to typical cosmetic loads [4]. This is why the readout separates two questions that are easy to merge. Does copper-tripeptide chemistry stimulate follicles? The mouse, ex vivo human follicle, and analog dermal-papilla data say yes within research models [9][13]. Does a given topical product deliver enough intact GHK-Cu to the dermal papilla to reproduce that? That depends entirely on formulation and route, and is not established for arbitrary products. The mechanism is supported; the delivery is the variable. ## What the hair record does and does not establish Read as a whole, the copper-peptide hair record is a stack of supportive signals with one controlled human endpoint and a real attribution gap. Confirmed within research: follicle stimulation in C3H mice [9]; anti-apoptotic, pro-proliferative effects on dermal papilla cells and ex vivo follicle elongation from the AHK-Cu analog [13]; a non-androgenic, angiogenesis-and-Wnt mechanism with no measured change in sex hormones [4]; and a significant 6-month hair-count gain for a GHK combination over placebo [4]. Not established: that pure GHK-Cu, alone, reproduces the 45-patient hair-count result, because that trial paired GHK with photodynamically active 5-aminolevulinic acid [4]. Also unestablished is any long-term durability beyond the studied windows, and any head-to-head ranking against standard hair interventions. The honest summary: a mechanistically coherent, animal- and analog-supported, combination-validated follicle effect — strong enough to take seriously as research, short of a pure-GHK-Cu human efficacy proof. The safety side of this picture, including the no-adverse-events finding, sits in the [copper peptide side effects](/side-effects) readout. --- A frosted-console readout of the GHK-Cu copper-tripeptide record — each finding logged green and each missing human datum flagged amber, with no clinic behind the glass and nothing on this panel for sale.